Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study

@article{Ghirlanda1993EvidenceOP,
  title={Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study},
  author={Giovanni Ghirlanda and Alessandro Oradei and Andrea Manto and Silvio Lippa and Luigi Uccioli and Salvatore Caputo and A. V. Greco and Gian Paolo Littarru},
  journal={The Journal of Clinical Pharmacology},
  year={1993},
  volume={33}
}
Inhibitors of HMG‐CoA reductase are new safe and effective cholesterol‐lowering agents. Elevation of alanine‐amino transferase (ALT) and aspartate‐amino transferase (AST) has been described in a few cases and a myopathy with elevation of creatinine kinase (CK) has been reported rarely. The inhibition of HMG‐CoA reductase affects also the biosynthesis of ubiquinone (CoQ10). We studied two groups of five healthy volunteers treated with 20 mg/day of pravastatin (Squibb, Italy) or simvastatin (MSD… Expand
The clinical use of HMG CoA‐reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications
The depletion of the essential nutrient CoQ10 by the increasingly popular cholesterol lowering drugs, HMG CoA reductase inhibitors (statins), has grown from a level of concern to one of alarm. WithExpand
Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
TLDR
Although HMG-CoA reductase inhibitors are safe and effective within a limited time horizon, continued vigilance of a possible adverse consequence from coenzyme Q10 lowering seems important during long-term therapy. Expand
The Effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10
TLDR
The biochemistry of CoQ10, its role in cellular metabolism and the available evidence linking possible coenzyme Q10 deficiency to statin therapy are reviewed. Expand
Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
TLDR
It is demonstrated that simvastatin lowers both LDL-C and apo B plasma levels together with the plasma and platelet levels of CoQ10, and that coQ10 therapy prevents both plasma and Platelet CoQ 10 decrease, without affecting the cholesterol lowering effect of simvastsatin. Expand
Plasma Coenzyme Q10 Predicts Lipid-lowering Response to High-Dose Atorvastatin.
TLDR
Baseline CoQ10:LDL-C ratio was associated with the degree of LDL-C response to atorvastatin, and the utility of Co Q10 as a predictor of atorVastatin response should be further explored in patients with dyslipidemia. Expand
Simvastatin‐induced lactic acidosis: A rare adverse reaction?
TLDR
Evidence that lactic acidosis may develop as a complication of simvastatin therapy is offered, offering evidence that interference of the mitochondrial respiratory chain may play a role in the toxicity of this class of drugs. Expand
Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio.
TLDR
It is concluded that statin therapy can be associated with high blood lactate/ pyruvate ratio suggestive of mitochondrial dysfunction, and it is uncertain to what extent low serum levels of ubiquinone could explain the mitochondrial dysfunction. Expand
Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors
TLDR
Investigation of patients with heterozygous familial hypercholesterolaemia who did not exhibit any symptoms or abnormalities in safety parameters during 6 months of treatment with various statins indicated that statin therapy may be associated with increased oxidation injury. Expand
HMG-CoA reductase inhibitors and coenzyme Q10.
TLDR
Although there is not much of a safety concern with coenzyme Q10 supplementation, there is also not enough evidence to support its routine use for preventing the adverse effects of statin therapy, and it is therefore not recommended for this purpose at this time. Expand
The role of coenzyme Q10 in statin-associated myopathy: a systematic review.
TLDR
It is concluded that there is insufficient evidence to prove the etiologic role of CoQ10 deficiency in statin-associated myopathy and that large, well-designed clinical trials are required to address this issue. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
TLDR
HMGRI-induced myopathy is a class effect in the rat, which is potentiated by CsA as the result of altered clearance and resultant increased tissue exposure, and may form the basis for decreased elimination and the resultant elevated systemic exposure. Expand
Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.
The effects and safety of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, were investigated alone or in association with cholestyramine in 66 patients withExpand
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
TLDR
Results are in accord with two previous trials with different pharmacologic agents and indicate that modification of lipoprotein levels with gemfibrozil reduces the incidence of coronary heart disease in men with dyslipidemia. Expand
Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy.
TLDR
A long-term open-label study was begun in November 1982 with the goal of determining if tolerance of CoQ 10 and clinical improvement were maintained over long periods of time and it was thought it improper to use untreated control subjects in a long- term study. Expand
Influence of lovastatin on the pharmacokinetics, toxicity and immunologic response of cyclosporine in the obese Zucker rat.
TLDR
The present data support the interaction between cyclosporine and lovastatin observed clinically, resulting in acute renal dysfunction, and caution should be exercised in their combined use. Expand
Evaluation of metabolic status in amiodarone-induced thyroid disorders: plasma coenzyme Q10 determination
TLDR
CoQ10 determination could be useful in discriminating ‘true’ from ‘pseudo’-hyperthyroid conditions, due to a contaminating effect of the iodinerepleted drug amiodarone. Expand
Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth.
The availability of compactin (ML-236B), a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl Coenzyme A reductase, has permitted the demonstration of a hitherto unsuspected aspect ofExpand
Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy.
TLDR
CoQ10 deficiency is established as a cause of a familial mitochondrial cytopathy and it is suggested that the disease results from a tissue-specific defect of CoQ10 biosynthesis. Expand
Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.
TLDR
It is postulate that hepatic dysfunction secondary to cyclosporine predisposed these patients to lovastatin-induced muscle damage, and use of this drug in cardiac and other organ transplant recipients should be accompanied by close surveillance of creatine kinase, hepatic transaminases, and cyclospora levels. Expand
Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations.
  • B. Frei, M. C. Kim, B. Ames
  • Chemistry, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1990
TLDR
The data together with previous work on the antioxidant function of ubiquinol reported in the literature strongly suggest that ubiqu inol-10 is an important physiological lipid-soluble antioxidant. Expand
...
1
2
3
4
5
...